10-Q: Inari Medical Reports Second Quarter 2024 Results with Revenue Growth and Increased Operating Expenses

Inari Medical's second quarter 2024 results show a revenue increase of 22.5% year-over-year, alongside a net loss due to higher operating expenses.

Summary

• Inari Medical reported a revenue of $145.8 million for the three months ended June 30, 2024, a 22.5% increase compared to $119.0 million for the same period in 2023.
• The company's gross profit was $125.8 million, with a gross margin of 86.3% for the quarter, slightly down from 88.4% in the prior year.
• Operating expenses totaled $148.3 million, driven by increases in research and development, selling, general, and administrative costs, as well as acquisition-related expenses and amortization of intangible assets.
• The company experienced a net loss of $31.3 million for the quarter, compared to a net income of $2.1 million in the same quarter of the previous year.
• For the six months ended June 30, 2024, revenue was $289.0 million, a 22.9% increase from $235.2 million in the same period of 2023.
• The net loss for the first six months of 2024 was $55.6 million, compared to a net loss of $0.1 million for the same period in 2023.
• As of June 30, 2024, Inari Medical had $70.1 million in cash and cash equivalents, $39.5 million in short-term investments, and an accumulated deficit of $104.0 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue growth is strong, the significant increase in operating expenses and the resulting net loss are concerning. The legal challenges and ongoing investigation add further uncertainty. The sentiment is neutral to slightly negative.

Positives

• Revenue increased by 22.5% in Q2 2024 compared to Q2 2023, indicating strong sales growth.
• The company launched VenaCore, a new product for DVT treatment, expanding its product portfolio.
• The company has a strong cash position with $109.7 million in cash, cash equivalents, restricted cash and short-term investments.
• The company continues to expand its sales territories and open new accounts.

Negatives

• The company experienced a net loss of $31.3 million in Q2 2024, a significant decrease from the net income of $2.1 million in Q2 2023.
• Operating expenses increased significantly, driven by higher R&D, SG&A, and acquisition-related costs.
• Gross margin decreased to 86.3% in Q2 2024 from 88.4% in Q2 2023.
• Interest income decreased due to lower cash balances invested in short-term investments.
• Income taxes increased due to prior utilization of tax credit carryforwards and a higher annual effective tax rate.

Risks

• The company is subject to a civil investigative demand from the U.S. Department of Justice related to the Anti-Kickback Statute and Civil False Claims Act.
• The company is involved in a patent infringement lawsuit against Imperative Care, Inc.
• The company is facing securities class action lawsuits alleging false or misleading statements regarding revenue and expenses.
• The company's future financial performance is subject to various risks, including competition, regulatory changes, and economic conditions.
• The company's ability to achieve future revenue-based milestone payments related to the LimFlow acquisition is dependent on the net revenue generated from the sale of the LimFlow system.

Future Outlook

The company anticipates that its cash and cash equivalents, short-term investments, and available borrowings will be sufficient to fund its cash requirements and operating expenses for at least the next 12 months. The company expects revenue to increase as it expands its offerings, grows its sales organization, adds customers, and expands physician adoption of its products.

Management Comments

• Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical.
• We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs.
• We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism (VTE), and four other disease states.
• We believe our mission-focused and highly-trained commercial organization provides a significant competitive advantage.
• We have developed systems and processes to harness the information gained from these relationships and we leverage this information to rapidly iterate our solutions, introduce and execute physician education and training programs and scale our sales organization.

Industry Context

The company operates in the medical device industry, specifically focusing on minimally invasive treatments for venous diseases. The acquisition of LimFlow expands the company's reach into chronic limb-threatening ischemia (CLTI) treatments. The company's growth is driven by increasing adoption of its products and expansion into new markets, which aligns with the broader trend of minimally invasive procedures gaining popularity in healthcare.

Comparison to Industry Standards

• Inari Medical's revenue growth of 22.5% in Q2 2024 is strong compared to the overall medical device industry, which typically sees single-digit growth rates.
• Companies like Penumbra, Inc. and Boston Scientific Corporation, which also operate in the thrombectomy space, have reported varying growth rates, but Inari's growth is notable.
• The company's gross margin of 86.3% is relatively high, indicating strong pricing power and efficient manufacturing processes, compared to other medical device companies.
• However, the net loss of $31.3 million in Q2 2024 is a concern, as many established medical device companies are profitable.
• The company's focus on venous diseases and its innovative approach to mechanical thrombectomy positions it well in a niche market, but it faces competition from larger players with broader product portfolios.

Legal Proceedings

• The company received a civil investigative demand from the U.S. Department of Justice related to the Anti-Kickback Statute and Civil False Claims Act.
• The company filed a patent infringement lawsuit against Imperative Care, Inc.
• The company is facing securities class action lawsuits alleging false or misleading statements regarding revenue and expenses.

Related Party Transactions

• The company utilizes MRI The Hoffman Group, a recruiting services company owned by the brother of a board member, for recruiting services.

Stakeholder Impact

• Shareholders are negatively impacted by the net loss and the legal proceedings.
• Employees may be impacted by the ongoing investigation and legal challenges.
• Customers (hospitals) may benefit from the company's innovative products and expanded offerings.
• Suppliers may benefit from the company's increased sales and manufacturing activities.
• Creditors may be impacted by the company's financial performance and legal risks.

Next Steps

• The company plans to continue its commercialization efforts to expand its sales force and enter new markets.
• The company will continue to advance research and development, including ongoing clinical studies.
• The company will continue to monitor and address the legal proceedings and civil investigative demand.
• The company expects to commence operations at its second manufacturing facility in Costa Rica in the fourth quarter of 2024.

Key Dates

Keywords

medical devices, thrombectomy, venous thromboembolism, deep vein thrombosis, pulmonary embolism, chronic limb-threatening ischemia, LimFlow, VenaCore, revenue, net loss, operating expenses, financial results